share_log
Breakings ·  Jun 1 20:11
Nuvation Bio Inc : Tumors Shrank in 91% of Taletrectinib-Treated Patients With Advanced Ros1-Positive Nsclc Who Were Ros1 Tki-Naïve
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment